Earnings ·
OnKure reports Q3 net loss of $17.8M and raises cash to $163.3M
OKUROnKure Therapeutics, Inc.
OnKure Therapeutics reported a third-quarter 2026 net loss of $17.8 million, or $0.36 per share, compared to a $14.7 million loss in the prior-year period. Research and development expenses increased to $15.1 million from $11.9 million, driven by higher outsourced preclinical costs and manufacturing expenses. The company ended the quarter with $163.3 million in cash, cash equivalents, and marketable securities, providing a runway into 2029. OnKure also announced the PANORAMA registry to study vascular anomalies and confirmed plans to submit IND applications for OKI-345 and OKI-355 in the first half of 2027. The company is a clinical-stage biopharmaceutical firm developing precision medicines for vascular anomalies and cancers.